|Other Names||Adapter molecule crk, Proto-oncogene c-Crk, p38, CRK|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP3446a was selected from the region of human Phospho-CRK-Y221. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||The Crk-I and Crk-II forms differ in their biological activities. Crk-II has less transforming activity than Crk-I. Crk- II mediates attachment-induced MAPK8 activation, membrane ruffling and cell motility in a Rac-dependent manner. Involved in phagocytosis of apoptotic cells and cell motility via its interaction with DOCK1 and DOCK4. May regulate the EFNA5-EPHA3 signaling.|
|Cellular Location||Cytoplasm. Cell membrane. Note=Translocated to the plasma membrane upon cell adhesion.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
CRK is a member of an adapter protein family that binds to several tyrosine-phosphorylated proteins. It has several SH2 and SH3 domains (src-homology domains) and is involved in several signaling pathways, recruiting cytoplasmic proteins in the vicinity of tyrosine kinase through SH2-phosphotyrosine interaction. The N-terminal SH2 domain of this protein functions as a positive regulator of transformation whereas the C-terminal SH3 domain functions as a negative regulator of transformation.
Bougneres, L., et al., J. Cell Biol. 166(2):225-235 (2004).Stoletov, K.V., et al., Exp. Cell Res. 295(1):258-268 (2004).Miller, C.T., et al., Oncogene 22(39):7950-7957 (2003).Sun, J., et al., J. Biol. Chem. 278(35):32794-32800 (2003).Zhang, X.A., et al., J. Biol. Chem. 278(29):27319-27328 (2003).
If you have any additional inquiries please email technical services at email@example.com.